Next Generation

There are two problems with almost all therapeutic agents we apply to the skin:

1. Too much of the product stays on top of the skin, whereby the therapeutic agent either dissipates into thin air or gets rubbed off (by clothing, etc.)

2. When the product actually gets absorbed into the skin, its “lasting power” is only 30-60 minutes

Lidocaine-based creams, used to treat inflammatory conditions such as hemorrhoidal pain and itch, are a great example. When applied, some of the cream remains unabsorbed on the skin’s surface and is wasted, and the cream that is absorbed by the skin provides relief for less than one hour. The user either has to re-apply the cream throughout the day--which is inconvenient, impractical, and sometimes impossible--or simply has to live with the pain and itch.

Zylo’s delivery system solves both of these problems.

Once loaded into our Nanopods, that same Lidocaine is delivered beneath the skin’s surface where it cannot be rubbed off. Lodged there, the Nanopods slowly decompose, gradually releasing the Lidocaine’s effective ingredients, providing sustained relief from the pain and itch for the next 24 hours.

By loading that same Lidocaine into our Nanopods™, however, one achieves a very different result: The Lidocaine-filled Nanopods™ immediately lodge themselves under the surface of the skin where they cannot be rubbed off, and the Nanopods™ slowly decompose, gradually releasing the Lidocaine over a 24+ hour period. Once-a-day application should relieve the pain/itch for an entire day.

The unique properties of the Nanopod™ sustained delivery system can be likened to a transdermal patch, but without the patch, as shown below:

The following images demonstrate our success with sustainability in pig skin, a close proxy for human skin.

These transformative results led the President of the NanoDermatology Society to remark that our technology represented the next generation of drug delivery and that “the clinical applications are endless.”

Furthermore, Nitric Oxide-loaded and allicin-loaded Nanopods™ break up and destroy biofilms, which, when combined with the sustained-delivery feature of the platform, make them an exquisite match with sinusitis and cystic fibrosis, where the biofilm (in the nasal cavities and the lungs, respectively) make it extremely challenging to treat the infection.

The Nanopod™ delivery system is a breakthrough technology that holds promise for the treatment of atopic dermatitis, leg ulcers, a variety of skin and soft tissue infections, inflammatory conditions of the skin (such as acne and hemorrhoids), erectile dysfunction, osteoarthritis, onychomycosis, dermatophytosis, and sickle cell anemia. Over 40 scientific peer-reviewed papers have been published demonstrating the efficacy and safety of several Nanopod™ encapsulated platforms including NO-releasing, curcumin-releasing, siRNA-releasing, and amphotericine-releasing Nanopods™ in a multitude of animal models (see Publications tab).

Shown below is Adam Friedman, M.D., being interviewed on the Society of Dermatology Physician Assistant's